{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:44:56Z","timestamp":1793213096099,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00277-024-05962-y","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T04:02:27Z","timestamp":1724990547000},"page":"4637-4642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lymphocyte recovery after bendamustine therapy in patients with mantle cell lymphoma. Results of a retrospective analysis and prognostic impact in the CAR-T era"],"prefix":"10.1007","volume":"103","author":[{"given":"Livia","family":"Donzelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Antonacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Zhdanovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Di Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Di Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"7","key":"5962_CR1","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.3109\/10428194.2013.842986","volume":"55","author":"E Derenzini","year":"2014","unstructured":"Derenzini E, Zinzani PL, Cheson BD (2014) Bendamustine: role and evidence in lymphoma therapy, an overview. Leuk Lymphoma 55(7):1471\u20131478. https:\/\/doi.org\/10.3109\/10428194.2013.842986","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"5962_CR2","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ et al (2005) Bendamustine plus Rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-hodgkin\u2019s lymphoma. J Clin Oncol 23(15):3383\u20133389. https:\/\/doi.org\/10.1200\/JCO.2005.08.100","journal-title":"J Clin Oncol"},{"issue":"1","key":"5962_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","volume":"17","author":"M Rummel","year":"2016","unstructured":"Rummel M, Kaiser U, Balser C, Study Group Indolent Lymphomas (2016) Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol 17(1):57\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(15)00447-7. Erratum in: Lancet Oncol. 2016;17(1):e6","journal-title":"Lancet Oncol"},{"issue":"9","key":"5962_CR4","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/j.1349-7006.2010.01635.x","volume":"101","author":"K Ohmachi","year":"2010","unstructured":"Ohmachi K, Ando K, Ogura M et al (2010) Japanese Bendamustine Lymphoma Study Group. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 101(9):2059\u20132064. https:\/\/doi.org\/10.1111\/j.1349-7006.2010.01635.x","journal-title":"Cancer Sci"},{"issue":"9873","key":"5962_CR5","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Study group indolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210. https:\/\/doi.org\/10.1016\/S0140-6736(12)61763-2. Erratum in: Lancet. 2013 Apr","journal-title":"Lancet"},{"issue":"1","key":"5962_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bcmd.2011.09.007","volume":"48","author":"C Visco","year":"2012","unstructured":"Visco C, Castegnaro S, Chieregato K et al (2012) The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol Dis 48(1):68\u201375. https:\/\/doi.org\/10.1016\/j.bcmd.2011.09.007","journal-title":"Blood Cells Mol Dis"},{"issue":"11","key":"5962_CR7","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","volume":"31","author":"C Visco","year":"2013","unstructured":"Visco C, Finotto S, Zambello R et al (2013) Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 31(11):1442\u20131449. https:\/\/doi.org\/10.1200\/JCO.2012.45.9842","journal-title":"J Clin Oncol"},{"issue":"1","key":"5962_CR8","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3026(16)30185-5","volume":"4","author":"C Visco","year":"2017","unstructured":"Visco C, Chiappella A, Nassi L et al (2017) Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol 4(1):e15\u2013e23. https:\/\/doi.org\/10.1016\/S2352-3026(16)30185-5","journal-title":"Lancet Haematol"},{"issue":"28suppl4","key":"5962_CR9","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"1","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, et al, ESMO Guidelines Committee (2017) Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 1(28suppl4):iv62\u2013iv71. https:\/\/doi.org\/10.1093\/annonc\/mdx223","journal-title":"Ann Oncol"},{"issue":"19","key":"5962_CR10","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123(19):2944\u20132952. https:\/\/doi.org\/10.1182\/blood-2013-11-531327","journal-title":"Blood"},{"key":"5962_CR11","doi-asserted-by":"publisher","unstructured":"Saito H, Maruyama D, Maeshima AM et al (2017) Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer 5(10):e362. https:\/\/doi.org\/10.1038\/bcj.2015.86. Erratum in: Blood Cancer J. 2017;7(11):e620","DOI":"10.1038\/bcj.2015.86"},{"issue":"2","key":"5962_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12308-009-0036-x","volume":"2","author":"W Klapper","year":"2009","unstructured":"Klapper W, Hoster E, Determann O et al (2009) Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2(2):103\u2013111. https:\/\/doi.org\/10.1007\/s12308-009-0036-x","journal-title":"J Hematop"},{"issue":"14","key":"5962_CR13","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A et al (2020) KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 382(14):1331\u20131342. https:\/\/doi.org\/10.1056\/NEJMoa1914347","journal-title":"N Engl J Med"},{"issue":"12","key":"5962_CR14","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain T, Bar M, Kansagra AJ et al (2019) Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-hodgkin lymphoma: an expert panel opinion from the American society for transplantation and cellular therapy. Biol Blood Marrow Transpl 25(12):2305\u20132321. https:\/\/doi.org\/10.1016\/j.bbmt.2019.08.015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"5962_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A et al (2023) Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol 41(3):555\u2013567. https:\/\/doi.org\/10.1200\/JCO.21.02370","journal-title":"J Clin Oncol"},{"issue":"2","key":"5962_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.23.01097","volume":"42","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni G, Navarro V, Mart\u00edn-L\u00f3pez A\u00c1 et al (2024) Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. J Clin Oncol 42(2):205\u2013217. https:\/\/doi.org\/10.1200\/JCO.23.01097","journal-title":"J Clin Oncol"},{"issue":"5","key":"5962_CR17","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/trf.14003","volume":"57","author":"ES Allen","year":"2017","unstructured":"Allen ES, Stroncek DF, Ren J et al (2017) Autologous lymphapheresis for the production of chimeric antigen receptor T cells. Transfusion 57(5):1133\u20131141. https:\/\/doi.org\/10.1111\/trf.14003","journal-title":"Transfusion"},{"issue":"2","key":"5962_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bjh.18831","volume":"202","author":"T Jo","year":"2023","unstructured":"Jo T, Yoshihara S, Okuyama Y et al (2023) Risk factors for CAR-T cell manufacturing failure among DLBCL patients: a nationwide survey in Japan. Br J Haematol 202(2):256\u2013266. https:\/\/doi.org\/10.1111\/bjh.18831","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05962-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05962-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05962-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T09:28:50Z","timestamp":1730712530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05962-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["5962"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05962-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the responsible institution and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from patients included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"L. Donzelli declares that she has no conflict of interest. M. Antonacci declares that he has no conflict of interest. N. Zhdanovskaya declares that she has no conflict of interest. L. Petrucci declares that he has no conflict of interest. M. Di Palma declares that she has no conflict of interest. M. Martelli received a speaker honorarium from Roche, Gilead, Eusapharma, Incyte, Janssen-Cilag, and Beigene and a grant for the advisory board from Roche, Gilead, Novartis, Takeda, Eusapharma, Incyte, Janssen-Cilag and BMS. A. Di Rocco received a speaker honorarium from Roche, Gilead, Janssen, and Abbvie; a grant from Takeda and Gilead; consulting fees from Roche, Takeda, Incyte, Gilead, Novartis and Eli-Lilly.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}